ArticleJournal of materials science. Materials in medicine2025
Glutathione-responsive folic acid modified fluorescent SBA-15 nanocarrier for simultaneous imaging and drug delivery in prostate cancer treatment.
Article in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stimuli-responsive bioengineered platforms for precision cancer therapy.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of imaging modalities and drug transport strategies has opened up exciting and innovative possibilities for simultaneously tracking and treating cancer, pushing the boundaries of current advancements. In this study, SBA-15 mesoporous silica nanoparticles (SBA-15 MSN) with a potent fluorescence emission were synthesized by a sol-gel method for targeted drug delivery. The enzalutamide (ENZ, anticancer drug) and folic acid (FA, targeting agent) were covalently conjugated to SBA-15 and the resulted FA-SBA-15/ENZ was loaded with thiolated nitrogen-doped carbon dots (SNCDs) as a fluorescent label for imaging. The drug loading efficiency was up to 69.95% and the disulfide linkage between the drug and SBA-15 provided the nanocarrier with redox-responsive capability for controlled drug release, and could be degraded by reducing agents such as dithiothreitol (DTT) or glutathione (GSH). The drug release behavior of the FA-SNCD@SBA-15/ENZ in the presence of GSH was very different from that in DTT as the loaded ENZ could be quickly released in the presence of GSH, but not in DTT. In addition, the toxicity of the synthesized nanocarriers with a certain amount of drug was evaluated using an MTT assay. The developed FA-SNCD@SBA-15/ENZ multifunctional nanocarrier showed higher cytotoxicity compared with the untreated drug and nanoparticles in the PC3 human prostate cancer cell line.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.